Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase II Trial in Patients with Thyroid Eye Disease

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Oct. 19, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, the clinical trial of its anti-FcRn...

Full "IntellAsia: Resources" article